Titan Medical to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum

Titan Medical Inc. (Titan or the Company) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in single-port minimally invasive surgery (MIS), today announced that David McNally, President and CEO of the Company, will present a corporate overview at the Canaccord Genuity Medical Technologies & Diagnostics Forum on Thursday, November 15 at 2:00 p.m. Eastern time. The Medical Technologies & Diagnostics Forum will be held November 15, 2018 at the Westin Grand Central in New York, NY.

Mr. McNallys presentation will be webcast live and available for replay in the Investors section of Titan Medicals website at titanmedicalinc.com/investors.

About Titan Medical

Titan Medical Inc. is focused on research and development through to the planned commercialization of computer-assisted robotic surgical technologies for application in minimally invasive surgery. The Company is developing the SPORT Surgical System, a single-port robotic surgical system. The SPORT Surgical System is comprised of a surgeon-controlled patient cart that includes a 3D high-definition vision system and multi-articulating instruments for performing MIS procedures, and a surgeon workstation that provides an advanced ergonomic interface to the patient cart and a 3D endoscopic view inside the patients body. Titan intends to initially pursue focused surgical indications for the SPORT Surgical System, which may include one or more of gynecologic, urologic, colorectal or general abdominal procedures.

For more information, please visit the Companys website at www.titanmedicalinc.com.

WANT TO BUILD A FINANCIAL EMPIRE?

Subscribe to the Global Banking & Finance Review Newsletter for FREE
Get Access to Exclusive Reports to Save Time & Money

By using this form you agree with the storage and handling of your data by this website. We Will Not Spam, Rent, or Sell Your Information.
All emails include an unsubscribe link. You may opt-out at any time. See our privacy policy.

LHA Investor Relations
Kim Sutton Golodetz, (212) 838-3777
[email protected]
or
Bruce
Voss, (310) 691-7100
[email protected]